News Snapshot:
A research team at the Henan Normal University told media that they are trying to release in the domestic market an oral COVID-19 drug as soon as December. The drug named Azvudine is currently under phase III clinical trials in the First Affiliated Hospital of Zhengzhou University in Zhengzhou, capital of Central China's Henan Province, news outlet The Paper reported on Tuesday. Phase III clinical trials on the drug are also currently taking place in Brazil and Russia. Azvudine is anti-HIV drug which acts as a reverse transcriptase inhibitor. In relation with the novel coronavirus, the drug also shows good...
